Patent · US Active

Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

US9017671B2 · kind B2 · utility

20Cited by

118References

14Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

James Andya · Millbrae, US
SHIANG C. GWEE · Pacifica, US
Jun Liu · South San Francisco, US
Ye Shen · Lo Wu, CN

Key dates

Filing date	Oct 25, 2012
Grant date	Apr 28, 2015
Priority date	—
Expiry date	Oct 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.